The Lancet

Publication date: 2012-11
Volume: 380 Pages: 1829 - 39
ISSN: 0140-6736, 1474-547X PMID: 23122650
DOI: 10.1016/S0140-6736(12)61768-1
Publisher: The Lancet Publishing Group

Author:

Coles, Alasdair J
Twyman, Cary L ; Arnold, Douglas L ; Cohen, Jeffrey A ; Confavreux, Christian ; Fox, Edward J ; Hartung, Hans-Peter ; Havrdova, Eva ; Selmaj, Krzysztof W ; Weiner, Howard L ; Miller, Tamara ; Fisher, Elizabeth ; Sandbrink, Rupert ; Lake, Stephen L ; Margolin, David H ; Oyuela, Pedro ; Panzara, Michael A ; Compston, D Alastair S ; CARE-MS II investigators,

Keywords:

Adjuvants, Immunologic, Administration, Cutaneous, Adolescent, Adult, Antibodies, Monoclonal, Humanized, Female, Humans, Immunosuppressive Agents, Infusions, Intravenous, Male, Middle Aged, Multiple Sclerosis, Relapsing-Remitting, Peptides, Recurrence, Treatment Outcome, Young Adult, Alemtuzumab, Glatiramer Acetate, CARE-MS II investigators, 11 Medical and Health Sciences, General & Internal Medicine

Abstract:

The anti-CD52 monoclonal antibody alemtuzumab reduces disease activity in previously untreated patients with relapsing-remitting multiple sclerosis. We aimed to assess efficacy and safety of alemtuzumab compared with interferon beta 1a in patients who have relapsed despite first-line treatment.